Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
Clinical Neuropharmacology|June 11, 2004
Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson diseaseV Mesnage, J L Houeto, A M Bonnet, et al.Neurology|April 10, 2002
Parkinson's disease and sleepiness: an integral part of PDI Arnulf, E Konofal, M Merino-Andreu, et al.Neurology|March 17, 2010
Practice Parameter: treatment of nonmotor symptoms of Parkinson disease [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of NeurologyT A Zesiewicz, K L Sullivan, I Arnulf, et al.Biological Psychiatry|August 22, 2001
Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorderP Quintin, C Benkelfat, J M Launay, et al.Brain : a Journal of Neurology|March 2, 2002
Clinical predictive factors of subthalamic stimulation in Parkinson's diseaseM L Welter, J L Houeto, S Tezenas du Montcel, et al.Brain : a Journal of Neurology|July 8, 2005
Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barré syndromeV Cochen, I Arnulf, S Demeret, et al.Movement Disorders : Official Journal of the Movement Disorder Society|August 2, 2001
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's diseaseO Rascol, I Arnulf, H Peyro-Saint Paul, et al.Journal of Neurology, Neurosurgery, and Psychiatry|June 7, 2006
Parkinson's disease with camptocormiaF Bloch, J L Houeto, S Tezenas du Montcel, et al.Journal of Molecular Neuroscience : MN|May 2, 2015
Parkinson's Disease Genetic Loci in Rapid Eye Movement Sleep Behavior DisorderZ Gan-Or, S L Girard, A Noreau, et al.Neurology|June 30, 2012
Environmental risk factors for REM sleep behavior disorder: a multicenter case-control studyR B Postuma, J Y Montplaisir, A Pelletier, et al.Pageof 7